相关临床试验
242
26 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
19
7.8%
Available
1
0.4%
已完成
99
40.9%
Enrolling By Invitation
2
0.8%
No Longer Available
1
0.4%
尚未招募
5
2.1%
招募中
35
14.5%
暂停
1
0.4%
终止
58
24.0%
Unknown
3
1.2%
撤回
18
7.4%
暂无批准数据
- Final analysis of the foundational JULIET trial confirms tisagenlecleucel (Kymriah) provides long-term survival benefits for patients with relapsed or refractory large B-cell lymphoma, with five-year overall survival reaching 32%. - The study demonstrates CAR-T cells remain detectable in patient blood more than five years post-treatment, supporting the therapy's persistence and earning it the nickname "the living drug." - Historical survival projections for this patient population were under 5-10% at five years, making the 56% survival rate among responders a significant clinical breakthrough. - CAR-T therapy utilization has expanded dramatically from fewer than 100 patients annually in the U.S. during the original study to approaching 6,000 patients per year currently.
- Oregon Health & Science University researchers have developed SU212, an experimental drug that suppresses tumor growth and metastasis in triple-negative breast cancer through a novel mechanism targeting the ENO1 enzyme. - The molecule operates through non-orthosteric inhibition, inducing degradation of enolase 1 rather than simply blocking it, disrupting cancer cells' metabolic advantage in humanized mouse models. - SU212 shows potential for treating other cancers with ENO1 dysregulation including gliomas, pancreatic cancer, and thyroid carcinoma, with particular promise for patients with concurrent metabolic diseases like diabetes. - The research team is now working to advance SU212 toward clinical trials, requiring substantial investment for FDA approval and human testing.
• OHSU researchers have developed innovative nanoparticles that significantly improve high-intensity focused ultrasound cancer treatments by reducing required energy levels up to 100-fold, minimizing damage to surrounding healthy tissues. • The engineered nanoparticles feature surface bubbles that release energy when targeted with ultrasound, plus peptide coatings that help them adhere to tumors and deliver chemotherapy drugs directly to cancer cells. • In preclinical melanoma models, the combination therapy led to complete tumor elimination in some cases and improved survival beyond 60 days, demonstrating potential for treating hard-to-reach tumors with minimal side effects.
